OBJECTIVES: To investigate the effect of pH and buffers on the degradation rate of flucloxacillin and to determine if flucloxacillin can be stabilised using a buffered diluent for up to 14 days when stored at 2°C-8°C including a 24-hour infusion period at 32°C in two elastomeric devices (Accufuser and INfusor LV) filled to 240âmL. Testing as per the NHS Pharmaceutical Quality Assurance Committee Yellow Cover Document (YCD) requirements. METHODS: A validated stability indicating high-performance liquid chromatography method was used for assessing the stability of flucloxacillin diluted in 0.3%âw/v citrate-buffered saline pH 7.0 when stored at 2°C-8°C in two ambulatory devices (Accufuser and INfusor LV). Flucloxacillin at 10âand 50âmg/mL diluted in 0.3%âw/v citrate-buffered saline pH 7.0 to a final volume of 240âmL and stored at 2°C-8°C, including 24âhours at 32°C, was tested from two batches in replicate (n=3) at five time points for up to 14 days according to the requirements of the YCD. RESULTS: Greater than 95% of the zero-time concentration of flucloxacillin at 10âand 50âmg/mL remained when stored at 2°C-8°C after 14 days including 24âhours at 32°C in both Accufuser and INfusor LV devices. CONCLUSIONS: Flucloxacillin sodium stability was improved, and complied with UK national standards, by using a diluent of 0.3%âw/v citrate-buffered saline pH 7 in both Accufuser and INfusor LV ambulatory devices when filled to 240âmL. The data support assigning a shelf-life of up to 14 days (13 days stored at 2°C-8°Câand 24âhours at 32°C). Flucloxacillin may now be used appropriately as a continuous 24-hour infusion in outpatient parenteral antimicrobial therapy services, providing further opportunity to avoid or shorten patient hospital stays, as well as support ideal antimicrobial stewardship principles.
Assessment of the stability of citrate-buffered flucloxacillin for injection when stored in two commercially available ambulatory elastomeric devices: INfusor LV (Baxter) and Accufuser (Woo Young Medical): a study compliant with the NHS Yellow Cover Document (YCD) requirements.
阅读:10
作者:Allwood Michael Charles, Stonkute Donata, Wallace Andrew, Wilkinson Alan-Shaun, Hills Tim, Jamieson Conor
| 期刊: | European Journal of Hospital Pharmacy-Science and Practice | 影响因子: | 1.500 |
| 时间: | 2020 | 起止号: | 2020 Mar;27(2):90-94 |
| doi: | 10.1136/ejhpharm-2018-001515 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
